For decades, general health and science information has served as a foundational resource for public understanding of medication risks and patient safety. This broad educational context has empowered individuals to recognize that certain prescription drugs, while effective for their intended uses, may carry significant long-term side effects. Within this legacy framework, the focus has been on raising awareness about adverse reactions and encouraging informed medical decision-making. As this general health perspective evolved, it became increasingly important to address specific, high-stakes scenarios where medication exposure intersects with legal and occupational realities. One such scenario involves prolonged use of Reglan (metoclopramide), a drug commonly prescribed for gastrointestinal disorders. Clinical experience has established that extended exposure to this medication can elevate the risk of developing tardive dyskinesia, a serious movement disorder. This risk is particularly relevant for individuals in occupational settings where fine motor control or public-facing roles are essential, as the condition's involuntary movements can directly impact job performance and safety. The transition from general health education to this targeted concern highlights a critical shift: from passive awareness to active risk management. For those who have taken Reglan over an extended period, understanding the legal dimensions—such as California's statute of limitations for filing a tardive dyskinesia claim—becomes a practical necessity. This pivot underscores the need to move beyond general knowledge and into actionable steps for those affected in their professional lives.
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the total duration of treatment with metoclopramide products, including Reglan tablets, should not exceed 12 weeks; if longer-term use is unavoidable, clinicians are advised to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information warns that Reglan is not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is also contraindicated in patients with Parkinson's disease, and concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome should be avoided (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
From a medical-legal perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning explicitly states that metoclopramide can cause TD and that the risk increases with treatment duration and cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, patients may have been prescribed Reglan for longer than the recommended 12-week period, or may not have been adequately informed about the risk of TD. The prescribing information also notes that Reglan has not been shown to be safe and effective for gastroesophageal reflux for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients who developed TD after prolonged use, the question of whether the prescribing physician or manufacturer provided sufficient warning may be relevant. Attorney-related considerations for affected patients include the statute of limitations for filing a claim in California. In California, the statute of limitations for personal injury claims, including those related to drug-induced TD, is generally two years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. For claims against a manufacturer, the timeline may also be affected by the date of last exposure to the drug. Patients who developed TD after taking Reglan should consult with an attorney to determine the applicable deadlines, as delays in filing can bar recovery. The timeline between exposure and documented harm is critical: TD may develop during treatment or after discontinuation, and symptoms may be masked by the drug itself, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delay can complicate the determination of when the statute of limitations begins to run. In summary, Reglan carries a well-documented risk of causing TD, with the risk increasing with longer use and higher cumulative doses. The drug is approved only for short-term use, and the prescribing information includes explicit warnings about TD. Patients who developed TD after taking Reglan may have legal recourse, but must be aware of California's statute of limitations, which typically requires filing within two years of discovering the injury. Consulting with an attorney experienced in pharmaceutical litigation is advisable to evaluate the specific circumstances of exposure, diagnosis, and any potential failure to warn.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In California, the statute of limitations for personal injury claims, including those related to drug-induced tardive dyskinesia, is generally two years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. For claims against a manufacturer, the timeline may also be affected by the date of last exposure to the drug. It is crucial to consult with an attorney promptly to avoid missing the deadline.
Tardive dyskinesia is often irreversible, as stated in the prescribing information for Reglan (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, in some cases, symptoms may improve or resolve after discontinuation of the drug, especially if caught early. Early detection and cessation of Reglan are critical to minimizing long-term effects.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.